Stockscreener 앱 받기
1.90
7.77%
-0.16
전일 마감가:
$2.06
열려 있는:
$2.05
하루 거래량:
573.19K
Relative Volume:
0.64
시가총액:
$117.07M
수익:
$40.37M
순이익/손실:
$-119.72M
주가수익비율:
-0.9313
EPS:
-2.0402
순현금흐름:
$-135.06M
1주 성능:
-22.45%
1개월 성능:
-37.70%
6개월 성능:
-52.02%
1년 성능:
-64.35%
1일 변동 폭
$1.89
$2.05
1주일 범위
$1.89
$2.47
52주 변동 폭
$1.89
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
명칭
Voyager Therapeutics Inc
전화
857-259-5340
주소
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
1.90 | 117.07M | 40.37M | -119.72M | -135.06M | -2.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-02 | 개시 | Citigroup | Buy |
| 2024-11-29 | 재개 | Wedbush | Outperform |
| 2024-10-16 | 개시 | Leerink Partners | Outperform |
| 2024-03-26 | 개시 | Guggenheim | Buy |
| 2024-03-19 | 개시 | H.C. Wainwright | Buy |
| 2024-03-07 | 개시 | Citigroup | Buy |
| 2024-01-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | 개시 | Truist | Buy |
| 2023-03-10 | 개시 | Oppenheimer | Outperform |
| 2021-10-07 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2021-02-03 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-24 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-11-10 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | 개시 | The Benchmark Company | Buy |
| 2020-02-06 | 개시 | Oppenheimer | Outperform |
| 2018-11-15 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-09-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | 개시 | H.C. Wainwright | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-03-12 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-02-02 | 개시 | Morgan Stanley | Overweight |
| 2017-11-28 | 재개 | Piper Jaffray | Overweight |
| 2017-10-31 | 개시 | Robert W. Baird | Outperform |
| 2017-10-27 | 개시 | Canaccord Genuity | Buy |
| 2017-10-23 | 재확인 | Stifel | Buy |
| 2017-10-12 | 개시 | Raymond James | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-28 | 재개 | Stifel | Buy |
모두보기
Voyager Therapeutics Inc 주식(VYGR)의 최신 뉴스
Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky - Simply Wall Street
Wave Life Sciences Ltd. (WVE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Abeona Therapeutics Inc. (ABEO) stock price, news, quote and history - Yahoo Finance UK
Voyager Technologies, Inc. Prices $350.0 Million Convertible Senior Notes Offering - Yahoo Finance
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes - Yahoo Finance
A $350 million raise could help Voyager expand and buy companies - Stock Titan
Protara Therapeutics (Nasdaq:TARA)Stock Analysis - Simply Wall Street
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Voyager Therapeutics at wells fargo healthcare conference: key data ahead By Investing.com - Investing.com Nigeria
Voyager Therapeutics at wells fargo healthcare conference: key data ahead - Investing.com
Voyager Therapeutics at wells fargo healthcare conference: key data ahead By Investing.com - Investing.com Canada
Voyager Therapeutics stock holds steady as investors watch gene therapy pipeline - ad-hoc-news.de
Voyager to Present at Upcoming Investor Conferences - markets.businessinsider.com
Voyager to Present at Upcoming Investor Conferences - GlobeNewswire
Transcript : Voyager Therapeutics, Inc.Special Call - marketscreener.com
Voyager Therapeutics Inc. (VYGR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Voyager Therapeutics (VYGR) Rises 2.3% as Gene Therapy Stock Approaches Key Resistance at $3.72Composite Profile - siam.in
Voyager Therapeutics (VYGR) Rises 2.3% as Gene Therapy Stock Approaches Key Resistance at $3.72Key Reversal Day - dars.gov.et
Voyager Therapeutics (VYGR) Rises 2.3% as Gene Therapy Stock Approaches Key Resistance at $3.72Diamond Pattern - dars.gov.et
Voyager Therapeutics Inc. (VYGR) Peer Comparison – Compare with Others - Value Research
H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy - Investing.com
Voyager Therapeutics (NasdaqGS:VYGR) Stock Forecast & Analyst Predictions - Simply Wall Street
Voyager Therapeutics (NASDAQ:VYGR) Stock Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Voyager Technologies (VOYG) opens flexible shelf to issue stock, debt and warrants - Stock Titan
Voyager Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | VT6 | US92915B1061 - marketscreener.com
Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares - Stock Titan
Voyager to Advance 2 Tau-Targeted Alzheimer Therapies Toward Key Clinical Milestones - NeurologyLive
Voyager’s New Alzheimer’s Trial Puts VYGR on Investors’ Early Watchlist - TipRanks
CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47% - simplywall.st
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47% - simplywall.st
HC Wainwright Brokers Raise Earnings Estimates for VYGR - MarketBeat
Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Teleflex (TFX) - The Globe and Mail
Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright - MarketBeat
VYGR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - moomoo.com
The Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
The Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Voyager Therapeutics (VYGR) Stock Rebounds While Cash Runway Concerns Persist - Sahm
Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates - Investing.com Nigeria
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Is Voyager Therapeutics Inc (VYGR) Overvalued After Q2 Earnings - GuruFocus
Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results - MarketBeat
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates - Investing.com
VYGR Looks 86.3% Overvalued on GF Value™ - GuruFocus
Voyager Therapeutics: Q2 Earnings Snapshot - Yahoo Finance
Voyager Therapeutics: Q2 Earnings Snapshot - KHOU
Voyager Therapeutics Inc (VYGR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Voyager Therapeutics Inc 주식 (VYGR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jorgensen Nathan D. | Former Officer |
May 15 '26 |
Proposed Sale |
4.24 |
9,406 |
39,881 |
0 |
| Sandrock Alfred | President and CEO |
Apr 02 '26 |
Sale |
3.87 |
11,511 |
44,548 |
472,549 |
| Sandrock Alfred | Officer |
Apr 02 '26 |
Proposed Sale |
3.87 |
11,511 |
44,597 |
0 |
| Swartz Robin | COO & CBO |
Feb 24 '26 |
Sale |
3.77 |
6,458 |
24,347 |
199,738 |
| Sandrock Alfred | President and CEO |
Feb 24 '26 |
Sale |
3.79 |
14,197 |
53,807 |
484,060 |
| Jorgensen Nathan D. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.77 |
4,668 |
17,598 |
151,416 |
| Carter Todd Alfred | Chief Scientific Officer |
Feb 24 '26 |
Sale |
3.76 |
4,174 |
15,694 |
145,718 |
| Carter Todd Alfred | Officer |
Feb 24 '26 |
Proposed Sale |
3.76 |
4,174 |
15,711 |
0 |
| Jorgensen Nathan D. | Officer |
Feb 24 '26 |
Proposed Sale |
3.77 |
4,668 |
17,588 |
0 |
| Swartz Robin | Officer |
Feb 24 '26 |
Proposed Sale |
3.77 |
6,458 |
24,335 |
0 |
4.22%
자본화:
|
볼륨(24시간):